1
|
Najafabadi MG, Gray GK, Kong LR, Gupta K, Perera D, Naylor H, Brugge JS, Venkitaraman AR, Shehata M. A transcriptional response to replication stress selectively expands a subset of Brca2-mutant mammary epithelial cells. Nat Commun 2023; 14:5206. [PMID: 37626143 PMCID: PMC10457340 DOI: 10.1038/s41467-023-40956-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 08/17/2023] [Indexed: 08/27/2023] Open
Abstract
Germline BRCA2 mutation carriers frequently develop luminal-like breast cancers, but it remains unclear how BRCA2 mutations affect mammary epithelial subpopulations. Here, we report that monoallelic Brca2mut/WT mammary organoids subjected to replication stress activate a transcriptional response that selectively expands Brca2mut/WT luminal cells lacking hormone receptor expression (HR-). While CyTOF analyses reveal comparable epithelial compositions among wildtype and Brca2mut/WT mammary glands, Brca2mut/WT HR- luminal cells exhibit greater organoid formation and preferentially survive and expand under replication stress. ScRNA-seq analysis corroborates the expansion of HR- luminal cells which express elevated transcript levels of Tetraspanin-8 (Tspan8) and Thrsp, plus pathways implicated in replication stress survival including Type I interferon responses. Notably, CRISPR/Cas9-mediated deletion of Tspan8 or Thrsp prevents Brca2mut/WT HR- luminal cell expansion. Our findings indicate that Brca2mut/WT cells activate a transcriptional response after replication stress that preferentially favours outgrowth of HR- luminal cells through the expression of interferon-responsive and mammary alveolar genes.
Collapse
Affiliation(s)
| | - G Kenneth Gray
- Department of Cell Biology, Harvard Medical School (HMS), Boston, MA, USA
| | - Li Ren Kong
- MRC Cancer Unit, University of Cambridge, Cambridge, UK
- The Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
- Department of Pharmacology, NUS School of Medicine, National University of Singapore, Singapore, Singapore
- NUS Centre for Cancer Research, National University of Singapore, Singapore, Singapore
| | - Komal Gupta
- MRC Cancer Unit, University of Cambridge, Cambridge, UK
- The Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
- NUS Centre for Cancer Research, National University of Singapore, Singapore, Singapore
| | - David Perera
- MRC Cancer Unit, University of Cambridge, Cambridge, UK
| | - Huw Naylor
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Joan S Brugge
- Department of Cell Biology, Harvard Medical School (HMS), Boston, MA, USA
| | - Ashok R Venkitaraman
- MRC Cancer Unit, University of Cambridge, Cambridge, UK.
- The Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
- Institute of Molecular & Cellular Biology Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore.
| | - Mona Shehata
- Department of Oncology, University of Cambridge, Cambridge, UK.
- MRC Cancer Unit, University of Cambridge, Cambridge, UK.
| |
Collapse
|
2
|
Prestel M, Prell-Schicker C, Webb T, Malik R, Lindner B, Ziesch N, Rex-Haffner M, Röh S, Viturawong T, Lehm M, Mokry M, den Ruijter H, Haitjema S, Asare Y, Söllner F, Najafabadi MG, Aherrahrou R, Civelek M, Samani NJ, Mann M, Haffner C, Dichgans M. The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1. Stroke 2019; 50:2651-2660. [PMID: 31500558 DOI: 10.1161/strokeaha.119.026112] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Background and Purpose- Genome-wide association studies have identified the HDAC9 (histone deacetylase 9) gene region as a major risk locus for atherosclerotic stroke and coronary artery disease in humans. Previous results suggest a role of altered HDAC9 expression levels as the underlying disease mechanism. rs2107595, the lead single nucleotide polymorphism for stroke and coronary artery disease resides in noncoding DNA and colocalizes with histone modification marks suggestive of enhancer elements. Methods- To determine the mechanisms by which genetic variation at rs2107595 regulates HDAC9 expression and thus vascular risk we employed targeted resequencing, proteome-wide search for allele-specific nuclear binding partners, chromatin immunoprecipitation, genome-editing, reporter assays, circularized chromosome conformation capture, and gain- and loss-of-function experiments in cultured human cell lines and primary immune cells. Results- Targeted resequencing of the HDAC9 locus in patients with atherosclerotic stroke and controls supported candidacy of rs2107595 as the causative single nucleotide polymorphism. A proteomic search for nuclear binding partners revealed preferential binding of the E2F3/TFDP1/Rb1 complex (E2F transcription factor 3/transcription factor Dp-1/Retinoblastoma 1) to the rs2107595 common allele, consistent with the disruption of an E2F3 consensus site by the risk allele. Gain- and loss-of-function studies showed a regulatory effect of E2F/Rb proteins on HDAC9 expression. Compared with the common allele, the rs2107595 risk allele exhibited higher transcriptional capacity in luciferase assays and was associated with higher HDAC9 mRNA levels in primary macrophages and genome-edited Jurkat cells. Circularized chromosome conformation capture revealed a genomic interaction of the rs2107595 region with the HDAC9 promoter, which was stronger for the common allele as was the in vivo interaction with E2F3 and Rb1 determined by chromatin immunoprecipitation. Gain-of-function experiments in isogenic Jurkat cells demonstrated a key role of E2F3 in mediating rs2107595-dependent transcriptional regulation of HDAC9. Conclusions- Collectively, our findings imply allele-specific transcriptional regulation of HDAC9 via E2F3 and Rb1 as a major mechanism mediating vascular risk at rs2107595.
Collapse
Affiliation(s)
- Matthias Prestel
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Caroline Prell-Schicker
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Tom Webb
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (T.W., M.G.N., N.J.S.)
| | - Rainer Malik
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Barbara Lindner
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Natalie Ziesch
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Monika Rex-Haffner
- Department of Translational Research in Psychiatry, Max-Planck-Institute for Psychiatry, Germany (M.R.H., S.R.)
| | - Simone Röh
- Department of Translational Research in Psychiatry, Max-Planck-Institute for Psychiatry, Germany (M.R.H., S.R.)
| | - Thanatip Viturawong
- Department of Proteomics and Signal Transduction, Max-Planck-Institute for Biochemistry, Martinsried, Germany (T.V., M.L., M. Mann)
| | - Manuel Lehm
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
- Department of Proteomics and Signal Transduction, Max-Planck-Institute for Biochemistry, Martinsried, Germany (T.V., M.L., M. Mann)
- Abteilung für Diagnostische und Interventionelle Neuroradiologie, Klinikum rechts der Isar, Munich, Germany (M.L.)
| | - Michal Mokry
- Department of Pediatrics (M. Mokry), University Medical Center Utrecht, the Netherlands
| | - Hester den Ruijter
- Laboratory of Experimental Cardiology (H.d.R., S.H.), University Medical Center Utrecht, the Netherlands
| | - Saskia Haitjema
- Laboratory of Experimental Cardiology (H.d.R., S.H.), University Medical Center Utrecht, the Netherlands
| | - Yaw Asare
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Flavia Söllner
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
- Department of Physiological Chemistry, Biomedical Center Munich, Ludwig-Maximilians-Universität München, Germany (F.S.)
| | - Maryam Ghaderi Najafabadi
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (T.W., M.G.N., N.J.S.)
| | - Rédouane Aherrahrou
- Center for Public Health Genomics, Department of Biomedical Engineering, University of Virginia, Charlottesville, (R.A., M.C.)
| | - Mete Civelek
- Center for Public Health Genomics, Department of Biomedical Engineering, University of Virginia, Charlottesville, (R.A., M.C.)
| | - Nilesh J Samani
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, United Kingdom (T.W., M.G.N., N.J.S.)
| | - Matthias Mann
- Department of Proteomics and Signal Transduction, Max-Planck-Institute for Biochemistry, Martinsried, Germany (T.V., M.L., M. Mann)
| | - Christof Haffner
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
| | - Martin Dichgans
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München, Germany (M.P., C.P.S., R.M., B.L., N.Z., M.L., Y.A., F.S., C.H., M.D.)
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (M.D.)
| |
Collapse
|
3
|
Jones PD, Kaiser MA, Ghaderi Najafabadi M, Koplev S, Zhao Y, Douglas G, Kyriakou T, Andrews S, Rajmohan R, Watkins H, Channon KM, Ye S, Yang X, Björkegren JLM, Samani NJ, Webb TR. JCAD, a Gene at the 10p11 Coronary Artery Disease Locus, Regulates Hippo Signaling in Endothelial Cells. Arterioscler Thromb Vasc Biol 2019; 38:1711-1722. [PMID: 29794114 DOI: 10.1161/atvbaha.118.310976] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Objective- A large number of genetic loci have been associated with risk of coronary artery disease (CAD) through genome-wide association studies, however, for most loci the underlying biological mechanism is unknown. Determining the molecular pathways and cellular processes affected by these loci will provide new insights into CAD pathophysiology and may lead to new therapies. The CAD-associated variants at 10p11.23 fall in JCAD, which encodes an endothelial junction protein, however, its molecular function in endothelial cells is not known. In this study, we characterize the molecular role of JCAD (junctional cadherin 5 associated) in endothelial cells. Approach and Results- We show that JCAD knockdown in endothelial cells affects key phenotypes related to atherosclerosis including proliferation, migration, apoptosis, tube formation, and monocyte binding. We demonstrate that JCAD interacts with LATS2 (large tumor suppressor kinase 2) and negatively regulates Hippo signaling leading to increased activity of YAP (yes-associated protein), the transcriptional effector of the pathway. We also show by double siRNA knockdown that the phenotypes caused by JCAD knockdown require LATS2 and that JCAD is involved in transmission of RhoA-mediated signals into the Hippo pathway. In human tissues, we find that the CAD-associated lead variant, rs2487928, is associated with expression of JCAD in arteries, including atherosclerotic arteries. Gene co-expression analyses across disease-relevant tissues corroborate our phenotypic findings and support the link between JCAD and Hippo signaling. Conclusions- Our results show that JCAD negatively regulates Hippo signaling in endothelial cells and we suggest that JCAD contributes to atherosclerosis by mediating YAP activity and contributing to endothelial dysfunction.
Collapse
Affiliation(s)
- Peter D Jones
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Michael A Kaiser
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Maryam Ghaderi Najafabadi
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Simon Koplev
- Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY (S.K., J.L.M.B.)
| | - Yuqi Zhao
- Department of Integrative Biology and Physiology, University of California, Los Angeles (Y.Z., X.Y.)
| | - Gillian Douglas
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre for Research Excellence (G.D., T.K., H.W., K.M.C.)
| | - Theodosios Kyriakou
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre for Research Excellence (G.D., T.K., H.W., K.M.C.).,Wellcome Trust Centre for Human Genetics (T.K.), University of Oxford, United Kingdom
| | - Sarah Andrews
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Rathinasabapathy Rajmohan
- National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Hugh Watkins
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre for Research Excellence (G.D., T.K., H.W., K.M.C.)
| | - Keith M Channon
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre for Research Excellence (G.D., T.K., H.W., K.M.C.)
| | - Shu Ye
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Xia Yang
- Department of Integrative Biology and Physiology, University of California, Los Angeles (Y.Z., X.Y.)
| | - Johan L M Björkegren
- Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY (S.K., J.L.M.B.).,Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden (J.L.M.B.).,Department of Physiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Estonia (J.LM.B.)
| | - Nilesh J Samani
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| | - Tom R Webb
- From the Department of Cardiovascular Sciences (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.).,National Institute for Health Research Leicester Cardiovascular Biomedical Research Centre (P.D.J., M.A.K., M.G.N., S.A., R.R., S.Y., N.J.S., T.R.W.), Glenfield Hospital, University of Leicester, United Kingdom
| |
Collapse
|
4
|
Aravani D, Morris GE, Jones PD, Tattersall HK, Karamanavi E, Kaiser MA, Kostogrys RB, Ghaderi Najafabadi M, Andrews SL, Nath M, Ye S, Stringer EJ, Samani NJ, Webb TR. HHIPL1, a Gene at the 14q32 Coronary Artery Disease Locus, Positively Regulates Hedgehog Signaling and Promotes Atherosclerosis. Circulation 2019; 140:500-513. [PMID: 31163988 PMCID: PMC6686954 DOI: 10.1161/circulationaha.119.041059] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Supplemental Digital Content is available in the text. Background: Genome-wide association studies have identified chromosome 14q32 as a locus for coronary artery disease. The disease-associated variants fall in a hitherto uncharacterized gene called HHIPL1 (hedgehog interacting protein-like 1), which encodes a sequence homolog of an antagonist of hedgehog signaling. The function of HHIPL1 and its role in atherosclerosis are unknown. Methods: HHIPL1 cellular localization, interaction with sonic hedgehog (SHH), and influence on hedgehog signaling were tested. HHIPL1 expression was measured in coronary artery disease–relevant human cells, and protein localization was assessed in wild-type and Apoe−/− (apolipoprotein E deficient) mice. Human aortic smooth muscle cell phenotypes and hedgehog signaling were investigated after gene knockdown. Hhipl1−/− mice were generated and aortic smooth muscle cells collected for phenotypic analysis and assessment of hedgehog signaling activity. Hhipl1−/− mice were bred onto both the Apoe−/− and Ldlr−/− (low-density lipoprotein receptor deficient) knockout strains, and the extent of atherosclerosis was quantified after 12 weeks of high-fat diet. Cellular composition and collagen content of aortic plaques were assessed by immunohistochemistry. Results: In vitro analyses revealed that HHIPL1 is a secreted protein that interacts with SHH and increases hedgehog signaling activity. HHIPL1 expression was detected in human smooth muscle cells and in smooth muscle within atherosclerotic plaques of Apoe−/− mice. The expression of Hhipl1 increased with disease progression in aortic roots of Apoe−/− mice. Proliferation and migration were reduced in Hhipl1 knockout mouse and HHIPL1 knockdown aortic smooth muscle cells, and hedgehog signaling was decreased in HHIPL1-deficient cells. Hhipl1 knockout caused a reduction of >50% in atherosclerosis burden on both Apoe−/− and Ldlr−/− knockout backgrounds, and lesions were characterized by reduced smooth muscle cell content. Conclusions: HHIPL1 is a secreted proatherogenic protein that enhances hedgehog signaling and regulates smooth muscle cell proliferation and migration. Inhibition of HHIPL1 protein function might offer a novel therapeutic strategy for coronary artery disease.
Collapse
Affiliation(s)
- Dimitra Aravani
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Gavin E Morris
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Peter D Jones
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Helena K Tattersall
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Elisavet Karamanavi
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Michael A Kaiser
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Renata B Kostogrys
- Department of Human Nutrition, Faculty of Food Technology, University of Agriculture in Kraków, Poland (R.B.K)
| | - Maryam Ghaderi Najafabadi
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Sarah L Andrews
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Mintu Nath
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Shu Ye
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Emma J Stringer
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Nilesh J Samani
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| | - Tom R Webb
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, United Kingdom (D.A., G.E.M., P.D.J., H.K.T., E.K., M.A.K., M.G.N., S.L.A., M.N., S.Y., E.J.S., N.J.S., T.R.W.)
| |
Collapse
|
5
|
Jones PD, Kaiser MA, Ghaderi Najafabadi M, McVey DG, Beveridge AJ, Schofield CL, Samani NJ, Webb TR. The Coronary Artery Disease-associated Coding Variant in Zinc Finger C3HC-type Containing 1 (ZC3HC1) Affects Cell Cycle Regulation. J Biol Chem 2016; 291:16318-27. [PMID: 27226629 PMCID: PMC4965579 DOI: 10.1074/jbc.m116.734020] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Indexed: 11/29/2022] Open
Abstract
Genome-wide association studies have to date identified multiple coronary artery disease (CAD)-associated loci; however, for most of these loci the mechanism by which they affect CAD risk is unclear. The CAD-associated locus 7q32.2 is unusual in that the lead variant, rs11556924, is not in strong linkage disequilibrium with any other variant and introduces a coding change in ZC3HC1, which encodes NIPA. In this study, we show that rs11556924 polymorphism is associated with lower regulatory phosphorylation of NIPA in the risk variant, resulting in NIPA with higher activity. Using a genome-editing approach we show that this causes an effective decrease in cyclin-B1 stability in the nucleus, thereby slowing its nuclear accumulation. By perturbing the rate of nuclear cyclin-B1 accumulation, rs11556924 alters the regulation of mitotic progression resulting in an extended mitosis. This study shows that the CAD-associated coding polymorphism in ZC3HC1 alters the dynamics of cell-cycle regulation by NIPA.
Collapse
Affiliation(s)
- Peter D Jones
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| | - Michael A Kaiser
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| | - Maryam Ghaderi Najafabadi
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| | - David G McVey
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| | - Allan J Beveridge
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| | - Christine L Schofield
- Horizon Discovery Limited, 7100 Cambridge Research Park, Waterbeach, Cambridge CB25 9TL, United Kingdom
| | - Nilesh J Samani
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| | - Tom R Webb
- From the Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, LE3 9QP and
| |
Collapse
|
6
|
Jones P, Kaiser M, Najafabadi MG, Webb T, Samani N. 210 Investigation of the Functional Role of the Lead Variant at the ZC3HC1 Coronary Artery Disease Locus in Cell Cycle Regulation using a Genome Editing Approach. Heart 2015. [DOI: 10.1136/heartjnl-2015-308066.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
7
|
Pawluczyk IZA, Ghaderi Najafabadi M, Patel S, Desai P, Vashi D, Saleem MA, Topham PS. Sialic acid attenuates puromycin aminonucleoside-induced desialylation and oxidative stress in human podocytes. Exp Cell Res 2013; 320:258-68. [PMID: 24200502 DOI: 10.1016/j.yexcr.2013.10.017] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Revised: 10/07/2013] [Accepted: 10/27/2013] [Indexed: 01/26/2023]
Abstract
Sialoglycoproteins make a significant contribution to the negative charge of the glomerular anionic glycocalyx-crucial for efficient functioning of the glomerular permselective barrier. Defects in sialylation have serious consequences on podocyte function leading to the development of proteinuria. The aim of the current study was to investigate potential mechanisms underlying puromycin aminonucleosisde (PAN)-induced desialylation and to ascertain whether they could be corrected by administration of free sialic acid. PAN treatment of podocytes resulted in a loss of sialic acid from podocyte proteins. This was accompanied by a reduction, in the expression of sialyltransferases and a decrease in the key enzyme of sialic acid biosynthesis N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE). PAN treatment also attenuated expression of the antioxidant enzyme superoxide dismutase (mSOD) and concomitantly increased the generation of superoxide anions. Sialic acid supplementation rescued podocyte protein sialylation and partially restored expression of sialyltransferases. Sialic acid also restored mSOD mRNA expression and quenched the oxidative burst. These data suggest that PAN-induced aberrant sialylation occurs as a result of modulation of enzymes involved sialic acid metabolism some of which are affected by oxidative stress. These data suggest that sialic acid therapy not only reinstates functionally important negative charge but also acts a source of antioxidant activity.
Collapse
Affiliation(s)
- Izabella Z A Pawluczyk
- Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Building, University Road, Leicester, LE1 9HN, UK; John Walls Renal Unit, Leicester General Hospital, Leicester, UK.
| | - Maryam Ghaderi Najafabadi
- Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Building, University Road, Leicester, LE1 9HN, UK
| | - Samita Patel
- Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Building, University Road, Leicester, LE1 9HN, UK; John Walls Renal Unit, Leicester General Hospital, Leicester, UK
| | - Priyanka Desai
- Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Building, University Road, Leicester, LE1 9HN, UK
| | - Dipti Vashi
- Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Building, University Road, Leicester, LE1 9HN, UK
| | - Moin A Saleem
- Academic and Children's Renal Unit, University of Bristol, Southmead Hospital, Bristol, UK
| | - Peter S Topham
- Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Building, University Road, Leicester, LE1 9HN, UK; John Walls Renal Unit, Leicester General Hospital, Leicester, UK
| |
Collapse
|